Branch² Intelligence
Biocon stock ticks up as Yesafili Biosimilar clinical data gets published in peer-reviewed journals
Key takeaway
Biocon's biosimilar Yesafili (aflibercept) clinical data published in peer-reviewed journals, advancing regulatory pathway.
- Step 1Biocon's Yesafili clinical data published in peer-reviewed journals, validating safety and efficacy.
- Step 2Regulatory filings in US and EU become more likely; Biocon's biosimilar programme gains credibility.
- Step 3Potential market entry of Yesafili could capture significant market share from Regeneron's Eylea, especially in price-sensitive segments.
- Step 4Biocon's contract manufacturing partners and suppliers see increased demand for biosimilar production.
Source: IN:The Hindu BusinessLine
This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.